Insider Selling: BioDelivery Sciences International, Inc. (BDSI) Director Sells 113,876 Shares of Stock

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Francis E. Odonnell, Jr. sold 113,876 shares of the firm’s stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $2.14, for a total value of $243,694.64. Following the completion of the sale, the director now directly owns 319,717 shares in the company, valued at approximately $684,194.38. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Shares of BDSI traded down $0.15 during trading hours on Monday, reaching $2.10. The stock had a trading volume of 154,043 shares, compared to its average volume of 510,776. BioDelivery Sciences International, Inc. has a 12 month low of $1.55 and a 12 month high of $3.60. The stock has a market capitalization of $131.51, a price-to-earnings ratio of -5.38 and a beta of 0.44. The company has a debt-to-equity ratio of 5.37, a quick ratio of 1.29 and a current ratio of 1.52.

How to Become a New Pot Stock Millionaire

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Thursday, March 15th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.05). BioDelivery Sciences International had a net margin of 8.52% and a return on equity of 22.93%. The firm had revenue of $12.51 million during the quarter, compared to the consensus estimate of $9.83 million. equities analysts forecast that BioDelivery Sciences International, Inc. will post -0.74 EPS for the current year.

A number of equities research analysts have weighed in on BDSI shares. Seaport Global Securities started coverage on BioDelivery Sciences International in a report on Friday, January 26th. They issued a “buy” rating and a $5.00 target price on the stock. Zacks Investment Research raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Wednesday, February 14th. ValuEngine downgraded BioDelivery Sciences International from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $5.00 target price on shares of BioDelivery Sciences International in a report on Thursday, March 15th. Finally, HC Wainwright set a $4.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a research note on Monday, March 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. BioDelivery Sciences International presently has an average rating of “Buy” and a consensus target price of $4.25.

A number of large investors have recently made changes to their positions in the stock. Broadfin Capital LLC raised its position in BioDelivery Sciences International by 5.1% during the 4th quarter. Broadfin Capital LLC now owns 4,634,119 shares of the specialty pharmaceutical company’s stock worth $13,671,000 after purchasing an additional 223,253 shares during the last quarter. Stonepine Capital Management LLC raised its position in BioDelivery Sciences International by 11.2% during the 3rd quarter. Stonepine Capital Management LLC now owns 3,867,400 shares of the specialty pharmaceutical company’s stock worth $11,409,000 after purchasing an additional 389,727 shares during the last quarter. Royce & Associates LP raised its position in BioDelivery Sciences International by 43.0% during the 4th quarter. Royce & Associates LP now owns 1,848,600 shares of the specialty pharmaceutical company’s stock worth $5,453,000 after purchasing an additional 555,800 shares during the last quarter. EAM Investors LLC raised its position in BioDelivery Sciences International by 62.1% during the 3rd quarter. EAM Investors LLC now owns 780,635 shares of the specialty pharmaceutical company’s stock worth $2,303,000 after purchasing an additional 299,163 shares during the last quarter. Finally, Northern Trust Corp raised its position in BioDelivery Sciences International by 0.9% during the 2nd quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock worth $394,000 after purchasing an additional 1,203 shares during the last quarter. 45.82% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This story was first published by Enterprise Leader and is owned by of Enterprise Leader. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://theenterpriseleader.com/2018/04/02/francis-e-odonnell-jr-sells-113876-shares-of-biodelivery-sciences-international-inc-bdsi-stock.html.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply